Background: Management of partial epilepsy is an important issue in the field of neurology. Objective: The purpose of the present study was to collect additional clinical data on efficacy and safety of sustained release sodium valproate chrono formulation as first-line monotherapy in patients newly or recently diagnosed with partial epilepsy in Bangladesh under daily practice condition.
efficacy and relatively good tolerance 2 . For the treatment of generalized epileptic syndromes sodium valproate is recognized as the drug of first choice [3] [4] [5] . On the other hand, in focal onset or partial epilepsy syndromes, carbamazepine is the most widely used agent in first-line treatment 6 . The effectiveness of valproate in controlling partial seizures has been shown comparable to that of carbamazepine in a number of randomized, controlled clinical trials 7-,10 .
Introduction
Epilepsy is a disorder of the brain that is characterized by an enduring predisposition to generate seizures and by its neurobiological, cognitive, psychological, and social consequences 1 . Around 30 to 40% of patients have seizures that are generalized at onset and rest is partial seizures. Sodium valproate has been widely used in treatment of epilepsy for nearly 40 years due to its wide spectrum of Journal of National Institute of Neurosciences Bangladesh, January 2015, Volume 1, Number 1 pISSN 2410-8030 (idiopathic, symptomatic or cryptogenic). Patient's overall assessment to the therapy was evaluated at the end of the study. Safety was assessed by recording of spontaneouslyreported adverse events throughout the study. Adverse events were classified according to severity, and relationship with treatment. Statistical analysis was based on intention to treat (ITT) population who were included in the study and exposed to at least one dose of treatment. Statistical analysis was mainly descriptive and was summarized as mean, median, standard deviation, minimum, maximum and percentages. The efficacy outcome measures were estimated at 95% confidence interval and compared with chi-square test. Statistical analysis was done using SPSS 17.0.
Results
All of the enrolled 300 patients took at least one dose of valproate therapy and were considered as ITT population. Among the patients 38 (12.7%) discontinued the study and the reasons were lost to follow-up (7.7%), lack of drug efficacy (2.3%) and poor compliance to protocol (2.7%).
One hundred and fifteen (38.3%) of the ITT population were children (15 years) and 185 (61.7%) were adults with higher male representation (71.3% & 83.7%). Of the patients 46 (15.3%) had relevant medical history of encephalitis, head injury, febrile illness, birth trauma or premature birth though no abnormality was reported by the physicians on brief neurological examination. At inclusion the mean duration of epilepsy was 4.4 months (SD 0.8 months) at inclusion. The most common seizures type reported was complex partial seizures (46%) and etiologically seizures were frequently idiopathic (41%) in nature. The topographic localization was not determined by the investigators. The demographic and clinical characteristics of study subjects are presented in Table 1 .
Sustained release formulation of sodium valproate has also been shown effective as first-line monotherapy in focal onset epilepsy with acceptable tolerability 11 . Epilepsy is a common neurological condition in Bangladesh. Though there are no national statistics, it is estimated that approximately 1.5 to 2.0 million people are suffering from epilepsy. For treating partial epilepsy carbamazepine is also conventionally used as first-line treatment in neurological practice. The objective of this observational study to collect additional clinical data on efficacy and safety of sustained release sodium valproate chrono formulation as first-line monotherapy in patients newly or recently diagnosed with partial epilepsy in Bangladesh under daily practice condition.
Methodology
This open-label, multicenter, non-controlled, prospective, observational study was conducted in a daily neurological practice condition in Bangladesh. In this study 300 patients with partial epilepsy who met inclusion criteria were consecutively enrolled by 5 investigators between March 2010 and February 2011. Adults and children 6 years and above, newly or recently diagnosed with partial epilepsy, with or without secondary generalized seizures for whom physicians decided to prescribe valproate sustained-release as first-line monotherapy were included in this study on receiving consent from patients or guardians for children. Newly diagnosed case was defined as at least 2 and no more than 10 partial seizures with or without secondary generalization during the past 6 months. Patients with primary generalized seizures or generalized epilepsy syndromes (Juvenile Myoclonlic Epilepsy), history of nonepileptic seizures were excluded to participate in this study. Exclusion criteria were also included pregnancy, lactation, hypersensitivity to valproate, liver disease, active CNS illness also those taking valproate 30 days prior to enrolment in this study. The patients were prescribed sustained release formulation of sodium valproate (Epilim Chrono®) according to local prescribing information and on investigator's discretion. Dose adjustment was also made at investigator's decision to achieve maximal therapeutic benefit (free from seizure) for individual patient. Treatment duration was for 6 months. Patients were followed-up at 1, 3 and 6 months. Patient data was collected by the investigators at baseline and during follow-up visits using paper copy of Data Collection Forms (DCF) provided for each patient. After completion of the study (i.e. after 6 months) the patient was managed according to the decision of the physician. The primary endpoint evaluation criterion was the remission rate defined as the proportion of seizurefree patients at 6 months. Secondary endpoints were the proportion of seizure-free patients at 1 and 3 months, the retention rate defined as the proportion of patients continuing treatment at 6 months, neurological status described from brief neurological evaluation, Clinical Global Impression. Subgroup efficacy outcome were also evaluated according to age group (children < 15 years or adults), seizure type (simple partial, complex partial or secondary generalized tonic-clonic seizures), and aetiology 
Short-term efficacy of valproate sustained-release as first-line monotherapy in partial epilepsy

Conclusion
This observational study supports that sodium valproate sustained formulation for first-line treatment of partial epilepsy in both adults and children is effective with acceptable tolerability in daily neurological practice condition.
The mean daily valproate dose prescribed in children at inclusion was 328.7 mg (SD 129 mg; median 300 mg; range 200 -800 mg) and 568 mg (SD 209 mg; median 500 mg; range 300 -1000 mg) in adults. The mean treatment duration in both children and adults was 5.5 months (SD 1.2 months; median 6 months; minimum 1.4 to maximum 6 months). At 6 months of therapy the overall remission rate was 74.7% (224). In children the rate was significantly higher (79.1% vs. 71.9%; p = 0.041). Remission rates were similar in etiologically not determined and idiopathic seizures. According to the seizure types remission rates varied with higher trends in patients with complex partial and secondary generalized tonic clonic seizures than simple partial type (79.7% and 71.1% vs. 68.6%). The number of seizure free patients also increased from 0 at baseline to 109 (36.3%) at month 1 and 175 (58.3%) at month 3. At the end of 6 months the overall retention rate was 87.3% with slight insignificant higher trend in adults than children (88.6% vs. 85.2%). On brief neurological examination no abnormality was reported by the investigators at the end of the study. Clinical Global Impression (CGI) assessment data was not available for 79 cases (26.3%) however improvement was rated as "marked" in 86.8% and "moderate" in 13.1% of cases on the basis of available data. No severe adverse event was reported in this study. However, 9.3% of patients experienced side effects like drowsiness and weight gain.
Discussion
The purpose of this study was to collect additional data on the effectiveness of valproate sustained-release as first-line monotherapy in patients with partial epilepsy in Bangladesh. The subjects were enrolled consecutively by 5 investigators at their daily neurological practice. Adults and children 6 years and above newly or recently diagnosed with partial epilepsy with or without secondary generalized seizures for whom investigators decided to prescribe valproate sustained-release as first-line monotherapy were included in this study. The primary endpoint was the remission rate defined as the proportion of seizure-free patients at 6 months. Remission rate at 1 and 3 months were also evaluated. The overall remission rate at 6 months of valproate sustained-release was 74.7% (224). In children the rate was significantly higher (79.1% vs. 71.9%; p = 0.041). The number of seizure free patients also increased from 0 at baseline to 109 (36.3%) at month 1 and 175 (58.3%) at month 3. At the end of 6 months the overall retention rate was 87.3% with small higher trend in adults (88.6%) than children (85.2%). Only 9.3% of patients experienced side effects like drowsiness and weight gain. No severe adverse
